U.S. markets close in 28 minutes
  • S&P 500

    4,138.33
    -41.43 (-0.99%)
     
  • Dow 30

    33,928.64
    -125.30 (-0.37%)
     
  • Nasdaq

    12,016.55
    -184.27 (-1.51%)
     
  • Russell 2000

    1,984.98
    -16.24 (-0.81%)
     
  • Crude Oil

    73.22
    -2.66 (-3.51%)
     
  • Gold

    1,878.50
    -52.30 (-2.71%)
     
  • Silver

    22.38
    -1.24 (-5.23%)
     
  • EUR/USD

    1.0804
    -0.0107 (-0.98%)
     
  • 10-Yr Bond

    3.5320
    +0.1360 (+4.00%)
     
  • GBP/USD

    1.2055
    -0.0174 (-1.42%)
     
  • USD/JPY

    131.0690
    +2.4650 (+1.92%)
     
  • BTC-USD

    23,367.72
    -446.56 (-1.88%)
     
  • CMC Crypto 200

    535.15
    -1.71 (-0.32%)
     
  • FTSE 100

    7,901.80
    +81.64 (+1.04%)
     
  • Nikkei 225

    27,509.46
    +107.41 (+0.39%)
     

FDA Puts Partial Hold On Aeglea's Rare Disorder Trial In Pediatric Patients

  • Aeglea BioTherapeutics Inc (NASDAQ: AGLEreceived an FDA letter responding to a recently submitted protocol amendment for the Phase 1/2 trial of pegtarviliase for Classical Homocystinuria.

  • Classical Homocystinuria is a rare disorder of methionine metabolism, leading to an abnormal accumulation of homocysteine and its metabolites in blood and urine.

  • The protocol amendment requested the inclusion of adolescent patients at clinical trial sites in the U.S.

  • The FDA stated that the protocol did not provide adequate justification and evidence to support the prospect of direct clinical benefit for pediatric patients.

  • Also ReadAeglea Bio Feels FDA Refusal Pinch, Cuts Workforce, Shifts Pipeline Focus

  • The agency placed the trial on partial clinical hold for enrolling patients under 18 years of age under this Investigational New Drug (IND).

  • The company believes the letter will not impact the planned enrollment and dosing of patients aged 18 & above.

  • Enrollment in the trial remains on track, and Aeglea continues to expect to announce data in the fourth quarter of 2022, including data from cohort 3.

  • Price Action: AGLE shares are down 3.64% at $0.53 on the last check Tuesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.